P-519. Detection & Severity of Respiratory Virus Co-Infections with SARS-CoV-2, Influenza, or RSV in U.S. Children <2 Years Old

Abstract Background Co-infections with multiple respiratory viruses may increase the severity of illness in young children, introducing a greater healthcare burden compared to single respiratory virus infections. Methods We conducted a national cohort study of Medicaid-enrolled children aged 0-24 months presenting for outpatient or inpatient care and tested by multiplex RT-PCR for SARS-CoV-2, influenza, and RSV between 1 July 2021 and 31 December 2022 using the Merative® MarketScan Multi-State Medicaid Database. ICD-10-CM and procedure codes were used to identify clinical diagnoses and the date of clinical testing. We compared the odds of outpatient encounters returning for additional outpatient care, receiving nebulizer treatment, and requiring hospitalization and the odds of inpatient encounters developing pneumonia, receiving noninvasive/invasive ventilation, or requiring critical care by co-infection status using Firth’s penalized logistic regression. Adjusted odds ratios (aOR) controlled for infant sex, age, week of diagnosis, and underlying health conditions. Results Among 40,527 outpatient encounters, 13,230 (33%) were positive for a respiratory virus: 5,621 (14%) for SARS-CoV-2 only, 5,030 (12%) for RSV only, 2,230 (5.5%) for influenza only, and 349 (0.9%) for multiple viruses. Among 954 inpatient encounters, 310 (32%) were positive for a respiratory virus: 211 (22%) for RSV only, 70 (7.3%) for SARS-CoV-2 only, 15 (1.6%) for influenza only, and 14 (1.5%) for multiple viruses. The most common co-infection was SARS-CoV-2 and RSV for outpatient (n=215/349; 62%) and inpatient co-infections (n=8/14; 57%)(Figure). The odds of returning to outpatient care (aOR: 2.16; 95%CI 1.64, 2.84), receiving nebulizer treatment (aOR: 6.33; 95%CI 3.36, 11.21), and hospitalization (aOR: 3.41; 95%CI 1.59, 6.56) were higher among SARS-CoV-2 co-infections compared to SARS-CoV-2 only (Table). In-hospital outcomes did not differ by co-infection status. Conclusion Children with an outpatient-attended SARS-CoV-2 or influenza co-infection, which were mostly attributed to RSV, more frequently required hospitalization and additional medical care. Given the burden of RSV and co-infections, RSV prevention remains a priority and a possibility through maternal vaccine and monoclonal antibodies. Disclosures Annette Regan, PhD, MPH, Moderna: DSMB Membership Stacey Rowe, PhD, MPH, CSL Seqirus: Advisor/Consultant Flor M. Munoz, MD, Merck: Advisor/Consultant|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support Sheena G. Sullivan, PhD, Astra-Zeneca: Advisor/Consultant|CSL Behring and CSL Seqirus: Advisor/Consultant|GSK: Advisor/Consultant|Moderna: Advisor/Consultant|Novavax: Advisor/Consultant|Pfizer: Advisor/Consultant|Sanofi: Advisor/Consultant

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2026-01-01
DOI
https://doi.org/10.1093/ofid/ofaf695.734
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P-519. Detection & Severity of Respiratory Virus Co-Infections with SARS-CoV-2, Influenza, or RSV in U.S. Children <2 Years Old

Annette K. Regan, Eileen K. Fry-Bowers, Onyebuchi A. Arah, Stacey Rowe et al.
Open Forum Infectious Diseases
Respiratory viral infections research
article

P-519. Detection & Severity of Respiratory Virus Co-Infections with SARS-CoV-2, Influenza, or RSV in U.S. Children <2 Years Old

Annette K. Regan, Eileen K. Fry-Bowers, Onyebuchi A. Arah, Stacey Rowe, Flor M Munoz
article en

Abstract

Abstract Background Co-infections with multiple respiratory viruses may increase the severity of illness in young children, introducing a greater healthcare burden compared to single respiratory virus infections. Methods We conducted a national cohort study of Medicaid-enrolled children aged 0-24 months presenting for outpatient or inpatient care and tested by multiplex RT-PCR for SARS-CoV-2, influenza, and RSV between 1 July 2021 and 31 December 2022 using the Merative® MarketScan Multi-State Medicaid Database. ICD-10-CM and procedure codes were used to identify clinical diagnoses and the date of clinical testing. We compared the odds of outpatient encounters returning for additional outpatient care, receiving nebulizer treatment, and requiring hospitalization and the odds of inpatient encounters developing pneumonia, receiving noninvasive/invasive ventilation, or requiring critical care by co-infection status using Firth’s penalized logistic regression. Adjusted odds ratios (aOR) controlled for infant sex, age, week of diagnosis, and underlying health conditions. Results Among 40,527 outpatient encounters, 13,230 (33%) were positive for a respiratory virus: 5,621 (14%) for SARS-CoV-2 only, 5,030 (12%) for RSV only, 2,230 (5.5%) for influenza only, and 349 (0.9%) for multiple viruses. Among 954 inpatient encounters, 310 (32%) were positive for a respiratory virus: 211 (22%) for RSV only, 70 (7.3%) for SARS-CoV-2 only, 15 (1.6%) for influenza only, and 14 (1.5%) for multiple viruses. The most common co-infection was SARS-CoV-2 and RSV for outpatient (n=215/349; 62%) and inpatient co-infections (n=8/14; 57%)(Figure). The odds of returning to outpatient care (aOR: 2.16; 95%CI 1.64, 2.84), receiving nebulizer treatment (aOR: 6.33; 95%CI 3.36, 11.21), and hospitalization (aOR: 3.41; 95%CI 1.59, 6.56) were higher among SARS-CoV-2 co-infections compared to SARS-CoV-2 only (Table). In-hospital outcomes did not differ by co-infection status. Conclusion Children with an outpatient-attended SARS-CoV-2 or influenza co-infection, which were mostly attributed to RSV, more frequently required hospitalization and additional medical care. Given the burden of RSV and co-infections, RSV prevention remains a priority and a possibility through maternal vaccine and monoclonal antibodies. Disclosures Annette Regan, PhD, MPH, Moderna: DSMB Membership Stacey Rowe, PhD, MPH, CSL Seqirus: Advisor/Consultant Flor M. Munoz, MD, Merck: Advisor/Consultant|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support Sheena G. Sullivan, PhD, Astra-Zeneca: Advisor/Consultant|CSL Behring and CSL Seqirus: Advisor/Consultant|GSK: Advisor/Consultant|Moderna: Advisor/Consultant|Novavax: Advisor/Consultant|Pfizer: Advisor/Consultant|Sanofi: Advisor/Consultant

Open Forum Infectious DiseasesVol. 13(Supplement_1)
Kaiser Permanente (US), University of California, Los Angeles (US), Baylor College of Medicine (US), Baylor School (US), Monash University (AU), University of San Francisco (US)
Good health and well-being
Openalex Percentile: Top 91%
Respiratory viral infections research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.